Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin biosimilars - Bioton

Next Previous
Drug Profile

Insulin biosimilars - Bioton

Alternative Names: Insulin analogues; Recombinant insulins

Latest Information Update: 21 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BIOTON
  • Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Diabetes mellitus

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 20 Jun 2018 Biomm plans a phase I trial for Type-1 diabetes mellitus in comparison with Humulin® in Brazil (RBR7mvgfc)
  • 22 May 2018 BIOMM S.A and Instituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda plans a phase I trial for type 1 Diabetes mellitus in Brazil (RBR8b9npb)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top